Eisai Co., Ltd. - Product Pipeline Review - 2016

  • ID: 3845347
  • Company Profile
  • 181 pages
  • Global Markets Direct
  • Eisai Co
1 of 4
Eisai Co., Ltd. - Product Pipeline Review - 2016

Summary

‘Eisai Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Eisai Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Eisai Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Eisai Co., Ltd.
- The report provides overview of Eisai Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Eisai Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Eisai Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Eisai Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Eisai Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Eisai Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Eisai Co., Ltd. Snapshot

Eisai Co., Ltd. Overview

Key Information

Key Facts

Eisai Co., Ltd. - Research and Development Overview

Key Therapeutic Areas

Eisai Co., Ltd. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Eisai Co., Ltd. - Pipeline Products Glance

Eisai Co., Ltd. - Late Stage Pipeline Products

Eisai Co., Ltd. - Clinical Stage Pipeline Products

Eisai Co., Ltd. - Early Stage Pipeline Products

Eisai Co., Ltd. - Drug Profiles

donepezil hydrochloride

eribulin mesylate

lenvatinib mesylate

lorcaserin hydrochloride

mitiglinide

perampanel

clevudine

mecobalamin

avatrombopag

fosravuconazole

lemborexant

BAN-2401

denileukin diftitox

E-2609

E-3710

E-7820

indisulam

Vaccine for Metastatic Melanoma

E-6011

E-6201

E-7449

golvatinib + lenvatinib

golvatinib tartrate

tazemetostat

donepezil hydrochloride Patch

E-2027

E-7046

E-7090

E-7389LF

SJ-733

AT-791

E-2072

E-2508

E-5539

E-6446

ER-358063

ER-410660

ER-886046

ER-901356

Small Molecule for Epilepsy

Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders

Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders

Small Molecule to Inhibit Cytidine Deaminase for Oncology

Small Molecule to Inhibit GWT1 Protein for Malaria

E-209

Small Molecules for Bacterial Infections

Small Molecules for Chagas Disease

Small Molecules for Lymphatic Filariasis and Onchocerciasis

Small Molecules for Malaria

Small Molecules for Oncology

Small Molecules for Tuberculosis

TRI-4

Eisai Co., Ltd. - Pipeline Analysis

Eisai Co., Ltd. - Pipeline Products by Target

Eisai Co., Ltd. - Pipeline Products by Route of Administration

Eisai Co., Ltd. - Pipeline Products by Molecule Type

Eisai Co., Ltd. - Pipeline Products by Mechanism of Action

Eisai Co., Ltd. - Recent Pipeline Updates

Eisai Co., Ltd. - Dormant Projects

Eisai Co., Ltd. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Eisai Co., Ltd. - Company Statement

Eisai Co., Ltd. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Eisai Co., Ltd., Key Information

Eisai Co., Ltd., Key Facts

Eisai Co., Ltd. - Pipeline by Indication, 2016

Eisai Co., Ltd. - Pipeline by Stage of Development, 2016

Eisai Co., Ltd. - Monotherapy Products in Pipeline, 2016

Eisai Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016

Eisai Co., Ltd. - Partnered Products in Pipeline, 2016

Eisai Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016

Eisai Co., Ltd. - Out-Licensed Products in Pipeline, 2016

Eisai Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Eisai Co., Ltd. - Pre-Registration, 2016

Eisai Co., Ltd. - Filing rejected/Withdrawn, 2016

Eisai Co., Ltd. - Phase III, 2016

Eisai Co., Ltd. - Phase II, 2016

Eisai Co., Ltd. - Phase I, 2016

Eisai Co., Ltd. - Preclinical, 2016

Eisai Co., Ltd. - Discovery, 2016

Eisai Co., Ltd. - Pipeline by Target, 2016

Eisai Co., Ltd. - Pipeline by Route of Administration, 2016

Eisai Co., Ltd. - Pipeline by Molecule Type, 2016

Eisai Co., Ltd. - Pipeline Products by Mechanism of Action, 2016

Eisai Co., Ltd. - Recent Pipeline Updates, 2016

Eisai Co., Ltd. - Dormant Developmental Projects,2016

Eisai Co., Ltd. - Discontinued Pipeline Products, 2016

Eisai Co., Ltd., Subsidiaries 176List of Figures

Eisai Co., Ltd. - Pipeline by Top 10 Indication, 2016

Eisai Co., Ltd. - Pipeline by Stage of Development, 2016

Eisai Co., Ltd. - Monotherapy Products in Pipeline, 2016

Eisai Co., Ltd. - Partnered Products in Pipeline, 2016

Eisai Co., Ltd. - Out-Licensed Products in Pipeline, 2016

Eisai Co., Ltd. - Pipeline by Top 10 Target, 2016

Eisai Co., Ltd. - Pipeline by Route of Administration, 2016

Eisai Co., Ltd. - Pipeline by Molecule Type, 2016

Eisai Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll